logo

ACAD

Acadia Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
6.41 / 10
Outperform

Fundamentally, Acadia rates Outperform with a 6.4/10 rating. Strong cash‑to‑market and PB‑ROE metrics, solid asset‑to‑market positioning, and 11.9% YoY revenue growth support its health. However, revenue‑to‑market and gross profit margin lag, tempering the outlook.

Fundamental(6.41)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.58
Score1/3
Weight18.18%
1M Return4.95%
Total operating revenue (YoY growth rate %)
Value11.87
Score3/3
Weight4.70%
1M Return1.54%
Inventory turnover ratio
Value3.14
Score2/3
Weight-3.39%
1M Return-1.21%
Gross profit margin (%)
Value91.69
Score0/3
Weight-17.64%
1M Return-7.24%
PB-ROE
Value1.78
Score3/3
Weight37.82%
1M Return9.74%
Income tax / Total profit (%)
Value-181.49
Score3/3
Weight5.49%
1M Return1.47%
Fixed assets turnover ratio
Value20.28
Score2/3
Weight-1.60%
1M Return-0.51%
Cost of sales ratio (%)
Value8.31
Score2/3
Weight-11.58%
1M Return-4.42%
Asset-MV
Value-0.55
Score2/3
Weight46.62%
1M Return12.22%
Cash-MV
Value0.02
Score2/3
Weight21.42%
1M Return5.94%
Is ACAD undervalued or overvalued?
  • ACAD scores 6.41/10 on fundamentals and holds a Discounted valuation at present. Backed by its 39.89% ROE, 36.49% net margin, 9.05 P/E ratio, 2.88 P/B ratio, and 69.34% earnings growth, these metrics solidify its Outperform investment rating.